Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: J Immunol. 2017 Feb 27;198(7):2735–2746. doi: 10.4049/jimmunol.1600810

Figure 3. In vivo TH17 are metabolically inflexible.

Figure 3

(A–D) In vivo (red)- and in vitro (blue)-differentiated TH17 cells were treated for one hour with DMSO or oligomycin (1μM) and then stimulated with PMA/ionomycin. OCR was analyzed on a Seahorse Bioanalyzer (A); intracellular ATP was evaluated by bioluminescence (B,C); ECAR was analyzed on a Seahorse Bioanalyzer (D). (B,C) Results are expressed as percentage of DMSO-treated cells. (C) Arrows indicate time in which intracellular ATP was evaluated. (A–D) Representative of three independent experiments; *p < 0.001; N.S., not significant (unpaired Student’s t-test); error bars, SEM.